Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals IRWD
$ 3.54 3.36%

Quarterly report 2025-Q3
added 11-10-2025

report update icon

Ironwood Pharmaceuticals Cash Flow 2011-2026 | IRWD

Annual Cash Flow Ironwood Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

104 M 183 M 274 M 262 M 169 M 10.7 M -70.9 M -101 M -25.9 M -107 M -156 M -273 M -69.6 M -75.2 M

Depreciation & Amortization

1.2 M 1.2 M 1.4 M 1.5 M 2.3 M 5.6 M 3.9 M 6.4 M 10.3 M 11.6 M 12.3 M 11.7 M 11.3 M 10 M

Accounts Payables

2.13 M 7.83 M 483 K 935 K 661 K 3.98 M 18.1 M 16 M 17.7 M 8.59 M 9.75 M 10.1 M 14.2 M 6.44 M

Accounts Receivables

81.9 M 129 M 130 M 138 M 146 M 11.3 M 21 M 3.19 M 933 K 2.88 M 10 K 513 K 457 K 74 K

Total Inventories

- - - - - 648 K - 735 K 1.08 M - 4.95 M 22.1 M 6.7 M -

All numbers in USD currency

Quarterly Cash Flow Ironwood Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - 20 M - - - 45 M - - - 80.2 M - 195 M - 64.1 M - 197 M - 73.7 M - 117 M 63.7 M 43.6 M - -16.9 M -51.6 M -42.4 M - -80.2 M -53.6 M -30.9 M - -91.5 M -60.3 M -27.8 M - -6.75 M -6.1 M - - - - -35.8 M - - - -57.9 M - -231 M -173 M -93.2 M - -47.2 M -86.2 M -43.1 M - - - -

Depreciation & Amortization

- - 479 K - - - 513 K - - - 286 K - 1.08 M - 355 K - 1.16 M - 410 K - 3.14 M 1.32 M 682 K - 4.71 M 1.54 M 688 K - 3.16 M 2.19 M 1.79 M - 6.6 M 4.84 M 2.91 M 3.3 M 7.52 M 5.32 M 2.83 M - 8.83 M 6.04 M 2.89 M - 9.38 M 6.21 M 3.18 M - 8.65 M 5.58 M 2.79 M - 8.52 M 5.49 M 2.68 M - 7.32 M 5.04 M 2.13 M

Accounts Payables

1.61 M 1.39 M 5.83 M 2.13 M 3.24 M 3.23 M 6.22 M 7.83 M 4.7 M 3.5 M 118 K 483 K 795 K - 532 K 935 K 414 K 466 K 842 K 661 K 661 K 661 K 661 K 3.98 M 3.98 M 3.98 M 3.98 M 14.9 M 14.9 M 14.9 M 18.1 M 16 M 16 M 16 M 16 M 17.7 M 19.8 M 9 M 4.74 M 8.59 M 8.59 M 8.59 M 8.59 M 9.75 M 6.1 M 3.39 M 9.76 M 10.1 M 10.1 M 10.1 M 10.1 M 14.2 M 14.2 M 14.2 M 14.2 M 6.44 M 6.44 M 6.44 M 6.44 M

Accounts Receivables

120 M 86.2 M 39.8 M 81.9 M 76.2 M 58.1 M 72 M 129 M 124 M 119 M 116 M 130 M 131 M - 120 M 138 M 126 M 126 M 111 M 146 M 146 M 146 M 146 M 43.9 M 11.3 M 11.3 M 11.3 M 21 M 21 M 21 M 21 M 3.19 M 3.19 M 3.19 M 3.19 M 933 K 933 K 933 K 933 K 2.88 M 2.88 M 2.88 M 2.88 M 10 K 10 K 10 K 10 K 513 K 513 K 513 K 513 K 457 K 457 K 457 K 457 K 74 K 74 K 74 K 74 K

Total Inventories

- - - - - - - - - - - - - - - - - - - - - - - 648 K 648 K 648 K 648 K - 76 K 1.1 M 1.7 M 735 K 735 K 735 K 735 K 1.08 M 1.08 M 1.08 M 1.08 M - - - 4.95 M 5 M 4.95 M 4.95 M 4.95 M 22.1 M 22.1 M 22.1 M 22.1 M 6.7 M 6.7 M 6.7 M 6.7 M - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Ironwood Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.19 -9.77 % $ 226 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Cabaletta Bio Cabaletta Bio
CABA
$ 3.34 0.45 % $ 3.9 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Codexis Codexis
CDXS
$ 1.02 1.49 % $ 74.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.74 3.6 % $ 1.12 B canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 1.37 % $ 480 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.87 -0.39 % $ 116 M franceFrance
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.23 2.22 % $ 1.23 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 41.75 0.19 % $ 1.32 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 36.14 1.23 % $ 3.75 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.98 1.27 % $ 5.7 B irlandaIrlanda
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.77 2.99 % $ 2.91 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.41 -1.87 % $ 36.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.94 0.01 % $ 130 M usaUSA
Curis Curis
CRIS
$ 1.1 -3.51 % $ 6.94 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
CorMedix CorMedix
CRMD
$ 7.16 0.42 % $ 364 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 6.14 3.89 % $ 83.9 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.72 -2.34 % $ 4.84 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Altimmune Altimmune
ALT
$ 4.21 -2.32 % $ 299 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 3.88 -8.92 % $ 247 M usaUSA